Cathepsin W is required for escape of influenza a virus from late endosomes by Edinger, T O et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Cathepsin W is required for escape of influenza a virus from late endosomes
Edinger, T O; Pohl, M O; Yangüez, E; Stertz, S
Abstract: Human cathepsinW(CtsW) is a cysteine protease, which was identified in a genome-wide RNA
interference (RNAi) screen to be required for influenza A virus (IAV) replication. In this study, we show
that reducing the levels of expression of CtsW reduces viral titers for different subtypes of IAV, and we
map the target step of CtsW requirement to viral entry. Using a set of small interfering RNAs (siRNAs)
targeting CtsW, we demonstrate that knockdown of CtsW results in a decrease of IAV nucleoprotein
accumulation in the nuclei of infected cells at 3 h postinfection. Assays specific for the individual stages of
IAV entry further show that attachment, internalization, and early endosomal trafficking are not affected
by CtsW knockdown. However, we detected impaired escape of viral particles from late endosomes in
CtsW knockdown cells. Moreover, fusion analysis with a dual-labeled influenza virus revealed a significant
reduction in fusion events, with no detectable impact on endosomal pH, suggesting that CtsW is required
at the stage of viral fusion. The defect in IAV entry upon CtsW knockdown could be rescued by ectopic
expression of wild-type CtsW but not by the expression of a catalytically inactive mutant of CtsW,
suggesting that the proteolytic activity of CtsW is required for successful entry of IAV. Our results
establish CtsW as an important host factor for entry of IAV into target cells and suggest that CtsW
could be a promising target for the development of future antiviral drugs.
DOI: 10.1128/mBio.00297-15
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-119558
Published Version
 
 
Originally published at:
Edinger, T O; Pohl, M O; Yangüez, E; Stertz, S (2015). Cathepsin W is required for escape of influenza
a virus from late endosomes. mBio, 6(3):e00297-15. DOI: 10.1128/mBio.00297-15
Cathepsin W Is Required for Escape of Influenza A Virus from Late
Endosomes
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ABSTRACT Human cathepsinW (CtsW) is a cysteine protease, which was identified in a genome-wide RNA interference (RNAi)
screen to be required for influenza A virus (IAV) replication. In this study, we show that reducing the levels of expression of
CtsW reduces viral titers for different subtypes of IAV, and wemap the target step of CtsW requirement to viral entry. Using a
set of small interfering RNAs (siRNAs) targeting CtsW, we demonstrate that knockdown of CtsW results in a decrease of IAV
nucleoprotein accumulation in the nuclei of infected cells at 3 h postinfection. Assays specific for the individual stages of IAV
entry further show that attachment, internalization, and early endosomal trafficking are not affected by CtsW knockdown. How-
ever, we detected impaired escape of viral particles from late endosomes in CtsW knockdown cells. Moreover, fusion analysis
with a dual-labeled influenza virus revealed a significant reduction in fusion events, with no detectable impact on endosomal pH,
suggesting that CtsW is required at the stage of viral fusion. The defect in IAV entry upon CtsW knockdown could be rescued by
ectopic expression of wild-type CtsW but not by the expression of a catalytically inactive mutant of CtsW, suggesting that the
proteolytic activity of CtsW is required for successful entry of IAV. Our results establish CtsW as an important host factor for
entry of IAV into target cells and suggest that CtsW could be a promising target for the development of future antiviral drugs.
IMPORTANCE Increasing levels of resistance of influenza viruses to available antiviral drugs have been observed. Development of
novel treatment options is therefore of high priority. In parallel to the classical approach of targeting viral enzymes, a novel
strategy is pursued: cell-dependent factors of the virus are identified with the aim of developing small-molecule inhibitors
against a cellular target that the virus relies on. For influenza A virus, several genome-wide RNA interference (RNAi) screens re-
vealed hundreds of potential cellular targets. However, we have only limited knowledge on how these factors support virus repli-
cation, which would be required for drug development. We have characterized cathepsinW, one of the candidate factors, and
found that cathepsinW is required for escape of influenza virus from the late endosome. Importantly, this required the proteo-
lytic activity of cathepsinW.We therefore suggest that cathepsinW could be a target for future host cell-directed antiviral thera-
pies.
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Influenza is a febrile respiratory disease ofmedical and economicimportance in humans. The infectious agent of this disease, in-
fluenza A virus (IAV), is one of the best-studied viral pathogens.
Nevertheless, certain aspects of the infectious cycle remain elusive.
IAV belongs to the family Orthomyxoviridae, and it has a seg-
mented negative-sense single-stranded RNA genome (1). The
replication cycle of IAV starts with binding of the virus via its
glycoprotein hemagglutinin (HA) to N-acetylneuraminic acid
(sialic acid), a glycosylation motif on membrane proteins at the
surface of the airway epithelium (2). Attachment to target cells is
followed by internalization via clathrin- and non-clathrin-
mediated endocytosis or macropinocytosis (3–5). Internalized
particles are transported along the endosomal pathway, a complex
cellularmachinery, thatmediates the turnover of early endosomes
to late endosomes by fusion with lysosomal vesicles or proton
influx and acidification (6, 7). IAV exploits the acidification of
endosomes and fuses at lowpHwith the endosomalmembrane (8,
9). This fusion of viral and endosomal membranes allows the de-
livery of viral genomes in the form of viral ribonucleoproteins
(vRNPs) to the cytoplasm and their subsequent transport into the
nucleus, the site of IAV genome replication (10, 11). While the
functions of the viral proteins in the entry process are thought to
bewell understood,much less is known about the cellular proteins
involved. However, such cellular factors could potentially be ex-
ploited as drug targets for host-directed antiviral therapy if they
play a crucial role in IAV entry (12, 13). In order to reveal cellular
factors required for IAV, genome-wide RNA interference (RNAi)
screens have been performed (14–18). These screens have pro-
vided uswith hundreds of candidate factors, but to date, only a few
follow-up studies have been done.
In this study, we analyze the role of cathepsin W (CtsW) for
IAV replication, since CtsWwas discovered to be a required factor
for IAV, and it has been suggested that CtsW is involved in IAV
entry into cells in one of the RNAi screens (15). Cathepsins are
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cysteine proteases of the papain superfamily that are involved in
numerous cellular functions, such as regulation of apoptosis or
establishment of inflammatory processes (19). CtsW, together
with cathepsin F, belongs to a relatively new subgroup of F-like
cathepsins which is distinct from the well-studied cathepsin B-
and L-like subgroups (20). Cathepsins B and L were shown to be
required for Ebola virus entry by cleaving the viral glycoprotein in
the endosomal compartment (21). Moreover, inhibition of ca-
thepsin L also resulted in inhibition of severe acute respiratory
syndrome coronavirus (SARS-CoV) infection (22, 23), whereas
cathepsin B has been implicated in entry of Nipah virus (24). In
contrast to cathepsins B and L, nothing is known about the possi-
ble function of CtsW in viral infections. While cathepsins B and L
are lysosomal enzymes, CtsW was found to localize predomi-
nantly to the endoplasmic reticulum (ER) in HeLa, COS-7, and
natural killer (NK) cells (25, 26). Its high expression in CD8 T
cells and NK cells and its upregulation by interleukin 2 (IL-2) also
distinguish CtsW from the other members of the family (25). It
was observed that CtsW is not needed for the effector function of
these cells (26), so the question of the function of CtsW remains
unanswered.
Using assays specific for distinct stages of IAV entry, we show
here that CtsW plays a role in late endosomal escape of IAV and
that its cysteine protease activity is needed for this function. This
establishes CtsW as a novel host factor for entry of IAV and a
potential drug target.
RESULTS
Cathepsin W is required for influenza A virus multicycle
growth.Human cathepsinW (CtsW)was among the well-scoring
hits identified in a genome-wide RNAi screen for host factors re-
quired for IAV replication, and it was suggested that CtsW could
play a role in IAV entry (15). In order to confirm and extend these
findings, we analyzed the impact of small interfering RNA
(siRNA)-mediated CtsW knockdown on viral growth of IAV
strain A/WSN/33 at different times postinfection (p.i.) (Fig. 1A).
Depletion of CtsW using two different siRNAs (siCtsW #2 and
siCtsW#3)was found to reduce titers of A/WSN/33 up to 100-fold
compared to cells transfected with a nontargeting control siRNA
(siSCR). Cells treatedwith siRNAs targeting either a subunit of the
vacuolar ATPase (siVATPase) or the viral nucleoprotein (siNP)
showed an almost complete block of replication. siCtsW-
mediated reduction of viral titers was not limited to A549 cells, as
we observed similar effects in Wi38 lung fibroblast cells (Fig. 1B).
To check whether siCtsW treatment leads to a reduction in viral
titers for multiple IAV strains, we performed infection experi-
ments in siRNA-treated A549 cells with the highly pathogenic
avian strain A/FPV/Dobson/34 (H7N7) and the human strain
A/Hongkong/68 (H3N2) (Fig. 1C and D). Both viral strains
showed a significant decrease in viral replication at all time points
tested. To assess whether the observed inhibition was specific to
IAV, we analyzed the impact of CtsW knockdown on replication
of vesicular stomatitis virus (VSV). siCtsW treatment did not lead
to a significant reduction in VSV titers at 18 h p.i. (Fig. 1E), sug-
gesting that the requirement of CtsW is specific for IAV but inde-
pendent of the cell line and IAV strain.
Endogenous amounts of CtsW in A549 or Wi38 cells were too
low for detection in Western blots. Therefore, we tested the
knockdown efficiencies of the different siRNAs by cotransfecting
the siRNAs with a plasmid encoding CtsW and performed West-
ern blot analysis 48 h after transfection. Both siRNAs against CtsW
potently inhibited CtsW expression (Fig. 1F).
CathepsinW is required for an early step in influenzaAvirus
replication.Next, we evaluated the requirement of CtsW for early
stages of IAV infection. Using an immunofluorescence-based
read-out, we measured the amount of NP within cell nuclei of
siRNA-transfected A549 cells at early time points of infection. At
48 h after siRNA transfection, cells were infected with A/WSN/33
at amultiplicity of infection (MOI) of 5 and 3 h p.i. NPwas stained
and analyzed by confocal microscopy. In control cells treated with
siSCR, cell nuclei showed a clear signal ofNP, whereas cells treated
with siCtsW or the siVATPase control showed a drastic reduction
in nuclear NP (Fig. 2A). To exclude off-target effects, we repeated
this experiment using six different siRNAs targeting CtsW. For
each of the siRNAs, the NP signal at 3 h p.i. within cell nuclei (n
200) was quantified, and we observed a strong decrease compared
to siSCR-treated cells (Fig. 2B). All six siRNAs reduced the
plasmid-based expression of CtsW substantially (Fig. 2C), sug-
gesting that all of them are able to reduce endogenous levels of
CtsW below optimal amounts for IAV. In addition, no impact on
cell viability was observed for any of the siRNAs targeting CtsW
(Fig. 2D). These data indicate that CtsW is required for an early
step during the IAV replication cycle.
CathepsinW is not required for attachment, internalization,
and early endosomal trafficking of IAV. To further characterize
the function of CtsW in IAV replication, we tested the impact of
CtsWknockdownon the initial steps of the viral life cycle. First, we
examined the effect of siRNA-mediated knockdown of CtsW on
viral attachment and internalization using biotinylated IAV that
can be visualized with Cy3-labeled streptavidin. A549 cells were
transfected with the respective siRNAs, infected with biotinylated
IAV for 60 min on ice, which allows attachment but prevents
internalization, then fixed, and stained with Cy3-labeled strepta-
vidin. Flow cytometric analysis of membrane-bound virus re-
vealed no difference in the percentage of Cy3-positive (Cy3) cells
between siSCR- or siCtsW-treated cells (Fig. 3A, samples labeled 0
min), indicating that viral attachment is not affected by CtsW
knockdown. The signal was strongly reduced when cells were pre-
incubated with unlabeled streptavidin before fixation and Cy3
staining (Fig. 3A, samples labeled 0 min  Strep), showing that
the specific staining of membrane-bound virus can be blocked
with unlabeled streptavidin.
A second set of samples was transferred to 37°C after the infec-
tion on ice to allow internalization of the virus. At 30 min after
incubation at 37°C, the cells were eithermock treated or incubated
with unlabeled streptavidin, then fixed, and stained with Cy3-
labeled streptavidin (Cy3-streptavidin). Pretreatment with
streptavidin could only partially block the Cy3 signal, as internal-
ized virus particles will be protected from unlabeled streptavidin
(Fig. 3A, samples labeled 30 min Strep). Therefore, the ratio of
blocked to unblocked Cy3 labeling indicates the amount of inter-
nalized virus. As with the attachment, there was no significant
difference between cells transfected with siSCR and siCtsW
(Fig. 3A, bottom right graph). These data indicate that CtsW is not
required for attachment or internalization of IAV.
After attachment and internalization, the virus is transported
via the endosomal pathway through the cytoplasm. Endosomes
can be differentiated using a set of molecular markers, such as the
early endosomal antigen 1 (EEA1), which is a specific marker for
early endosomes. To elucidate whether CtsW plays a role in early
Edinger et al.
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endosomal trafficking, we transfected A549 cells with control siR-
NAs or siRNAs targeting CtsW and infected these cells with
A/WSN/33 at anMOI of 25. Viral infectionwas synchronizedwith
a cold binding step at 4°C for 1 h. After the cold binding step, the
inoculum was removed, the temperature was shifted to 37°C, and
cells were fixed at different time points (15 to 180 min) p.i. To
quantify the amount of viral NP in early endosomes, we per-
formed immunofluorescence analysis for NP and EEA1 andmea-
sured the percentage of NP colocalizing with EEA1 using Imaris
software. Between 15 and 180 min p.i., no difference in colocal-
ization of NP with the early endosomal marker was observed in
siSCR- or siCtsW-treated cells (Fig. 3B). Within the first 45 min
p.i., a rapid increase in colocalization of NP and EEA1 was de-
tected, and then colocalization declined, indicating a transient
presence of viral particles within the early endosomal compart-
ment. Representative images from the 45-min timepoint illustrate
the observed colocalization in both siSCR- and siCtsW-treated
cells (Fig. 3C; see Fig. S1 in the supplemental material). This sug-
gests that CtsW is not required for early endosomal trafficking and
that presumably, a later step is affected by CtsW knockdown.
Cathepsin W is required for late endosomal escape of influ-
enzaAvirus.Following the endosomal pathway, viral particles are
transported from early to late endosomes, where they encounter
low pH, which is required for fusion. To test whether CtsW is
required for trafficking through late endosomes, we transfected
A549 cells with siRNAs targeting CtsW or nontargeting control
siRNA and infected these cells with A/WSN/33 at an MOI of 25.
After an initial cold binding step of 1 h, the temperature was
FIG 1 Cathepsin W is required for replication of different strains of IAV. (A) A549 cells were transfected with different siRNAs, and 48 h posttransfection, the
cells were infected with A/WSN/33 (H1N1) at an MOI of 0.01. Supernatants were collected at the time points indicated on the x axis, and viral titers were
determined by immunofluorescence-based titration onVero cells. Virus titers were determined in focus-forming units permilliliter (ffu/ml). (B)Wi38 cells were
transfected and infected as described above for panel A. Viral titers were determined by plaque assay. Virus titers were determined in plaque-forming units per
milliliter (pfu/ml). (C and D) A549 cells were transfected with siRNAs, and 48 h posttransfection, the cells were infected with A/FPV/Dobson/34 (H7N7) at an
MOI of 0.001 (C) or A/Hongkong/68 (H3N2) at anMOI of 0.1 (D). Supernatants were collected at the indicated time points, and virus titration was performed
by plaque assay. (E) A549 cells were transfected with siRNAs, and 48 h after transfection, the cells were infected with vesicular stomatitis virus at anMOI of 0.001.
At 12 to 18 h p.i., supernatants were analyzed for viral growth by plaque assay on Vero cells. (F) A549 or Wi38 cells were cotransfected with a plasmid encoding
CtsW and two different siRNAs targeting CtsW or a nontargeting control siSCR. Efficiency of knockdown was analyzed by Western blotting (immunoblotting
[IB]) using a mouse monoclonal anti-CtsW antibody and an antibody against glyceraldehyde-3-phosphate dehydrogenase (GapDH) as loading control. The
positions of molecular mass markers (in kilodaltons) are indicated to the left of the blots. Panels A to E show representative results of at least two independent
experiments, each experiment performed in triplicate. Values are means standard deviations (error bars).
Role of Cathepsin W in Inﬂuenza A Virus Entry
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shifted to 37°C to allow virus entry. Incubation at 37°C was
stopped after 90 to 180 min p.i., and the cells were stained for NP
and the late endosomal marker lysobisphosphatidic acid (LBPA)
(27). We quantified the percentage of NP colocalizing with LBPA
using Imaris software. As expected, in siSCR-treated cells, colocal-
ization of NP and LBPAwas observed up to 120min p.i. (Fig. 3D).
Of note, the observed colocalization was less pronounced than
with the early endosomal marker, indicating a more rapid trans-
port through the late endosomal compartment. At 180 min p.i.,
NP no longer colocalized with LBPA in control cells; at this time,
NP was abundantly present within the nuclei of infected cells
(Fig. 3E, top row; see Fig. S1 in the supplemental material). In
contrast, cells treated with siCtsW displayed extended colocaliza-
tion of NP with LBPA. We observed that a majority of the NP
signal remained trapped in LBPA-positive compartments instead
of trafficking to the nucleus as shown in the representative image
of the 180-min p.i. time point (Fig. 3E, bottom row; Fig. S1).
To confirm that CtsW was required for incoming virions, we
repeated the experiment in the presence of cycloheximide, which
blocks translation and thus the synthesis of newNP.At 90min p.i.,
we observed equal amounts of NP colocalizing with LBPA in both
siSCR-transfected control cells and in siCtsW-transfected cells
(Fig. 3F). In contrast, at 120 min and 180 min p.i., we detected
more NP in LBPA-positive compartments in the siCtsW-
transfected cells, whereas nuclear NP became detectable only in
control cells (Fig. 3G; see Fig. S1 in the supplemental material).
Taken together, these results suggest that CtsW is required for
escape of IAV from late endosomes and/or transport of the RNPs
to the nucleus.
To distinguish between these two possibilities, we next
tested whether fusion of viral and endosomal membranes still
occurs in the absence of CtsW. We generated a dual-labeled
virus, which allowed us to measure fusion in a quantitative
manner. IAV particles were labeled with two different dyes, one
dye (R18 [octadecyl rhodamine B chloride] red) quenching the
fluorescence of the other dye {DiOC [3,3=-dioctadecyl-5,5=-
di(4-sulfophenyl)oxacarbocyanine] green}. If membrane fusion
occurs, DiOC andR18 diffuse into the endosomalmembrane, and
quenching is no longer possible, which enables the detection of
DiOC fluorescence. We infected siRNA-transfected A549 cells
that were either pretreated with dimethyl sulfoxide (DMSO) or
with bafilomycin A1, a known inhibitor of endosomal acidifica-
tion and viral fusion. We synchronized infection by adding the
virus in an initial 30-min cold binding step after which the tem-
perature was shifted to 37°C to allow viral entry and fusion. At 90
min or 180 min p.i., cells were analyzed by confocal microscopy,
and fusion sites were visible as bright green spots of DiOC fluo-
rescence. These fusion sites (white arrowheads in Fig. 4A) were
predominantly visible in siSCR-transfected control cells that were
pretreated with DMSO. Both siCtsW- and siVATPase-transfected
cells displayed fewer fusion sites as shown in representative images
(Fig. 4A). We quantified the number of fusion sites using the spot
detection algorithm of ImageJ and normalized to the number of
cell nuclei (Fig. 4B). We observed two to six fusion sites per cell at
90 to 180 min p.i. in siSCR-transfected cells pretreated with
DMSO. In contrast, no fusion sites were detected in siSCR-
transfected cells pretreated with bafilomycin A1. Also, in siCtsW-
and siVATPase-transfected cells, no or only a few fusion sites were
observed, independent of their pretreatment with DMSO or bafi-
FIG 2 Cathepsin W is required for an early step in the IAV replication cycle.
(A) A549 cells were transfected with the indicated siRNAs, and at 48 h post-
transfection, the cells were infectedwithA/WSN/33 (H1N1) at anMOI of 5. At
3 h p.i., cells were fixed and stained with a mouse monoclonal anti-NP anti-
body (green) and DAPI (blue) and analyzed by confocal microscopy. Bars,
20m. (B) This experiment was set up as described above for panel A. Nuclear
NP signal was quantified by ImageJ software using the DAPI signal for region
of interest (ROI) determination. Values aremeans of 200 cell nuclei per siRNA
with standard errors of the means indicated by the error bars. MFI, mean
fluorescence intensity. (C) Western blot for knockdown control was per-
formed by cotransfection of a CtsW-encoding plasmid and siRNAs into A549
cells. At 48 h posttransfection, cell lysates were analyzed for CtsW protein
expression by Western blotting using a mouse monoclonal anti-CtsW anti-
body and an antibody against GapDH as a loading control. (D) A549 cells were
transfected with the indicated siRNAs. At 48 h posttransfection, cell viability
was measured using the CellTiter-Glo luminescent cell viability assay. The
experiment was performed in triplicate, and error bars represent standard
deviations. In panels A to D, the results of one experiment that were represen-
tative of at least two independent experiments are shown.
Edinger et al.
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FIG 3 Knockdown of cathepsinW results in accumulation of NP in the late endosome. (A) A549 cells were transfected with siRNAs, and 48 h posttransfection,
the cells were infected on icewith biotinylatedA/WSN/33 for 1 h. Following attachment, the temperaturewas shifted to 37°C for 30min or cells were directly fixed
(samples labeled 0 min). Cells were treated with unlabeled streptavidin (samples labeled  Strep) or treated with PBS, then permeabilized and stained with
Cy3-labeled streptavidin. Flow cytometry analysis was performed, and the relative amount of virus bound to cells was calculated by subtracting the percentage
of Cy3-positive cells with streptavidin blocking from the percentage of Cy3-positive cells after PBS treatment (background subtraction). The relative amount of
internalized virus was calculated as a ratio between the amount of virus-positive cells at 30 min plus streptavidin and the amount of virus-positive cells 30 min
without streptavidin. (B to E) A549 cells were transfected with siRNAs, and 48 h later, the cells were infected with A/WSN/33 at anMOI of 25 for 1 h on ice. The
inoculum was washed off, and the temperature was shifted to 37°C. Samples were fixed and permeabilized at the indicated time points. Cells were stained with
amousemonoclonal anti-EEA1 antibody (B andC) ormousemonoclonal anti-LBPA (D and E) (plus secondary anti-mouse antibody conjugated to Alexa Fluor
(Continued)
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lomycin A1. This indicates that knockdown of CtsW results in
inhibition of viral and endosomal membrane fusion.
The siCtsW-mediated inhibition of fusion in late endosomes
raised the question whether CtsW localizes to late endosomal
compartments. Although previous studies reported ER localiza-
tion of CtsW (26, 28, 29), its production as an inactive precursor
in the ER couldmask its presence in other compartments. First, we
analyzed the localization of CtsW by costaining of CtsW and the
ER-resident chaperone calnexin in A549 cells stably expressing
CtsW. As expected, a large amount of CtsW colocalized with the
ERmarker (Fig. 4C, top panel).Unfortunately, wewere not able to
costain for CtsW and the late endosomal marker LBPA, as both
antibodies are derived from mice. We therefore costained for
LAMP1 as a marker for late endosomes and observed a consider-
able amount of colocalization (Fig. 4C, bottom panels). Thus, in
A549 cells, CtsW localizes to the ERbut also at least partially to late
endosomes where it could function to enable IAV fusion.
Cathepsin W is not required for acidification of endosomes
or another late fusing virus. Next, we tested whether the inhibi-
tion of viral fusion upon knockdown of CtsW was due to changes
in the pH of endosomes and a possible impact on acidification. To
this aim, we treated siRNA-transfected A549 cells with lysotracker
(LY), a dye that stains acidic compartments red fluorescent. As
expected, cells treated with the VATPase inhibitor bafilomycin A1
did not display any lysotracker signal (Fig. 5A, bottom row). Cells
transfected with siCtsW still displayed strong lysotracker staining
that was indistinguishable from control cells (Fig. 5A, top row),
suggesting that knockdown of CtsW does not drastically alter en-
dosomal pH and thereby inhibit fusion. However, it is still possi-
ble that minor changes in pH that are not detectable with the
lysotracker dye could contribute to the observed effects.We there-
fore tested the impact of CtsW knockdown on a strain of IAV,
A/duck/Ukraine/1/1963, that has recently been shown to have a
higher pH fusion optimum of pH 5.5 to 5.6 compared to pH 5.2
for A/WSN/33 (30). If reduced levels of CtsW resulted in slightly
increased endosomal pH, this virus strain should display reduced
sensitivity to knockdown of CtsW.We transfected A549 cells with
control or CtsW-targeting siRNAs, infected the cells with virus at
an MOI of 10, and quantified nuclear NP. We observed that
A/duck/Ukraine/1/1963 replicated more slowly than A/WSN/33
did and that nuclear NP was detected only from 5 h p.i. onwards
(data not shown).We therefore chose the 5-h time point to quan-
tify nuclear NP. Similar to the results obtained with A/WSN/33,
we detected a strong reduction in nuclear NP accumulation upon
knockdown of CtsW (Fig. 5B; see Fig. S2A in the supplemental
material). Next, we tested the impact of CtsW knockdown on
lymphocytic choriomeningitis virus (LCMV), which also fuses in
acidic compartments (31). Cells transfected with the control
siSCR displayed robust viral replication in the cytoplasm of in-
fected cells (Fig. 5C and Fig. S1B), whereas lower levels of viral NP
were detected in cells transfected with siVATPase. In cells trans-
fected with two siRNAs targeting CtsW, we could not detect any
significant changes in the cytoplasmic replication of LCMV, and
therefore, we conclude that, although LCMV is a late fusing virus,
it is not dependent on CtsW for fusion. These data suggest that
CtsW does not impact endosomal pH, yet it is required for viral
and endosomal fusion of IAV but not LCMV.
Cathepsin W does not cleave viral glycoproteins. Given that
other cathepsin family members have been shown to proteolyti-
cally process viral glycoproteins (21, 22, 32, 33), we next tested
whether CtsW cleaves IAV proteins on incoming virions. Since all
previous experiments were performed with stocks of IAV that
were grown in the presence of trypsin and thus contained HA1
and HA2 but no or negligible levels of HA0 (Fig. 5D), we did not
expect to find a role for CtsW in cleavage of HA0 to HA1/HA2.
However, additional cleavage events of hemagglutinin (HA) or
neuraminidase (NA) could be possible. We infected A549 control
cells or A549 cells overexpressing CtsW with A/WSN/33 (MOI of
50) for 1 h or 2 h. Cell lysates were prepared and tested for viral
protein levels and for CtsW expression. Since we mapped the tar-
get step of CtsW to an event at or just before fusion in the late
endosome, we did not expect NP or M1 matrix protein to be
proteolytically processed by CtsW. Indeed, the levels of M1 and
NPwere unchanged upon overexpression of CtsW, and no lower-
molecular-mass bands were observed (Fig. 5E; see Fig. S2C in the
supplemental material). Interestingly, we also found similar levels
of the two viral surface glycoproteins HA and NA (Fig. 5E and
Fig. S2C), and we could not detect any cleavage products with a
lower molecular mass for either protein. Thus, we assume that no
CtsW-dependent cleavage of viral surface glycoproteins takes
place.
The enzymatic activity of cathepsin W is required for influ-
enza A virus entry. To test whether its catalytic activity as cys-
teine protease is required for the function of CtsW in IAV
entry, we generated an enzymatically inactive mutant of CtsW,
CtsW(C153A), by replacing cysteine at position 153, which is part
of the catalytic triad by alanine. In addition, we introduced three
silent mutations to achieve resistance to one of our siRNAs (CtsW
#2) into both the wild-type CtsW- and CtsW(C153A)-encoding
constructs. Both constructs were cloned into a lentiviral vector
and used to generate stable cell lines expressing either CtsW
(CtsW_res #2) or CtsW(C153A) (C153A_res #2). In addition,
A549 cells were transduced with a lentivirus carrying no insert
(control cells). To validate the cell lines, theywere transfectedwith
either siRNAs targeting CtsW or control siSCR, and lysates were
analyzed by Western blotting for CtsW expression. As described
above, endogenous levels of CtsW were not detected. In contrast,
both cell lines transduced to express either wild-type CtsW or
CtsW(C153A) showed robust expression of CtsW when trans-
fected with siSCR or siCtsW #2 against which both constructs
weremade resistant (Fig. 6A). As expected, siCtsW#3was still able
to reduce CtsW levels below the limit of detection in Western
blots, validating the generated cell lines. In addition, we also as-
sessed growth of IAV in the cell lines overexpressing either wild-
Figure Legend Continued
546 [AF546]) and a rabbit anti-NP polyclonal serum (plus secondary anti-rabbit AF488). The amount of NP colocalizing with the respective marker was
quantified using the standard colocalization function of Imaris software for at least 10 cells per condition (B and D). Representative images are shown in panels
C and E. The values in panels B and D are mean percentages of NP colocalized with the marker standard deviations (error bars). Bars, 2 m. (F and G) Same
experimental setup as in panels B to E, but infection was performed in the presence of cycloheximide (100 g/ml). The results of one experiment that were
representative of two independent experiments are shown in panels A to G. (D to F) For significance testing, a two-tailed Student’s t test was performed (n 10).
Values that are significantly different are indicated by bars and asterisks as follows: **, P 0.01; ****, P 0.0001.
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type or mutant CtsW and found no difference in IAV replication
(see Fig. S3 in the supplemental material). Next, we made use of
the cell lines to assess whether the catalytic activity of CtsW was
required for its function in IAV entry. After transfection of CtsW-
targeting or control siRNAs, we infected these cells with
A/WSN/33 at an MOI of 10. After an initial cold binding step, we
allowed infection to proceed for 3 h at 37°C before we stained for
IAV NP and measured the NP signal within the nuclei of infected
cells. All three cell lines transfected with siSCR showed a clear NP
signal in the nucleus at 3 h p.i. (Fig. 6B). As expected, the nuclear
NP signal was strongly reduced in control cells upon knockdown
of CtsW with either of the two siRNAs (Fig. 6B, top row). In
contrast, CtsW_res #2 cells transfected with siCtsW #2 displayed a
significantly higherNP signal due to the overexpression of siRNA-
resistant CtsW. This effect was specific to siCtsW #2; transfection
of siCtsW #3 still resulted in a strongly reduced nuclear NP signal
(Fig. 6B, middle row). We could not observe a rescue of infection
in the siCtsW#2-transfected cells when the cells were overexpress-
ing catalytically inactive CtsW (Fig. 6B, bottom row). In addition,
we transfected the cell lines with an siRNA targeting the VATPase
subunit. Transduced cells, transfected with this siRNA, did not
show any infection which shows that the observed rescue of infec-
tion is specific to CtsW knockdown. To verify these findings, we
quantified the amounts of nuclear NP using ImageJ software. For
siCtsW #2, rescue of infection by wild-type CtsW was highly sig-
nificant compared to control cells, but expression of the inactive
mutant did not increase the levels of nuclear NP significantly
(Fig. 6C).
When staining the cell lines A549 CtsW_res #2 and A549
CtsW(C153A) _res #2 for CtsW by immunofluorescence, we ob-
served that only about 60% of all cells were positive (data not
shown). We hypothesized that this could be the reason for the
incomplete rescue of infection by wild-type CtsW. Indeed, when
we repeated the experiment but stained for CtsW and NP in par-
allel and quantified only nuclear NP from CtsW-positive cells, we
observed an almost complete rescue of nuclear NP (Fig. 6D).
Taken together, overexpression of CtsW can rescue the effect of
siRNA-mediated knockdown of CtsW, showing that the observed
impact on IAV entry is caused by depletion of CtsW levels rather
than off-target effects of the siRNA. Moreover, the proteolytic
activity of CtsW is required for its role in escape of IAV from late
endosomes.
FIG 4 Knockdown of cathepsin W prevents fusion of viral and endosomal
membranes. (A and B) A549 cells were transfected with siRNAs, and 48 h later,
the cells were infected with a dual-labeled A/PR/8 virus (DiOC green and R18
red). Before the cells were infected, they were pretreated with DMSO or 10 nM
bafilomycin A1 (BafA1) for 2 h. The virus was bound to cells for 30 min in a
(Continued)
Figure Legend Continued
cold binding step (4°C), and then the cells were incubated for 90 to 180min at
37°C to allow viral entry and fusion. Images were acquired by confocalmicros-
copy without fixation and permeabilization of the samples. (A) Representative
images from the 180-min p.i. time point are shown. The green spots in the
siSCRDiOCpanel and thewhite arrowheads indicate fusion sites. Bars, 10m.
(B) Quantification of fusion sites was performed by spot analysis for the green
DiOC signal using ImageJ software and 4magnified images. Spot size was set
at 20 pixels. The number of fusion sites was normalized to the number of cell
nuclei. Values are mean numbers of fusion sites standard deviations (error
bars). For significance testing, a two-tailed Student’s t test was used (n 10).
Values that are significantly different are indicated by bars and asterisks as
follows: ****, P  0.0001. (C) A549 cells stably overexpressing CtsW were
stained for CtsW with a mouse monoclonal antibody against CtsW and a
rabbit polyclonal antibody against calnexin (top panels) or a rabbit polyclonal
antibody against LAMP1 (bottom panels). Bars, 10 m. In panels A to C, the
results of one experiment representative of two independent experiments are
shown.
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FIG 5 Cathepsin W is not required for acidification and does not cleave viral proteins. (A) A549 cells were transfected with the indicated siRNAs and either
treatedwithDMSOor bafilomycin A1 for 2 h at 48 h posttransfection. Cells were then labeledwith lysotrackerDND-99 (red), and confocal images were acquired
from unfixed samples. DAPI staining was introduced by the mounting medium. Bars, 5 m. (B) A549 cells were transfected with siRNAs and infected with the
indicated virus (MOI of 10) at 48 h posttransfection. Cells were fixed 5 h p.i., stained for viral NP using a mouse monoclonal NP antibody (plus secondary
antibody anti-mouse AF488) and DAPI. Nuclear NP signal was quantified with ImageJ software. Mean values are shown with the standard errors of the means
indicated by the error bars. Values that are significantly different by a two-tailed Student’s t test are indicated by bars and asterisks as follows: ****, P 0.0001
(n 100). (C) A549 cells were transfected with siRNAs and infected with lymphocytic choriomeningitis virus (LCVM) at an MOI of 2 at 48 h posttransfection.
Cells were fixed 7 h p.i., stained for LCMV NP using a mouse monoclonal LCMV NP antibody (plus secondary antibody anti-mouse AF488) and DAPI.
Cytoplasmic LCMVNP signalwas quantifiedwith ImageJ software.Mean values are shownwith the standard error of themean indicated by the error bars. Values
that are not significantly different (P  0.05) by a two-tailed Student’s t test are indicated (n.s.) (n  64). (D) An aliquot of A/WSN/33 used in the previous
experiments was lysed and prepared for SDS-PAGE, then viral proteins were separated on SDS-polyacrylamide gels and transferred byWestern blotting, andHA
was detected using a mouse monoclonal antibody specific for HA of A/WSN/33. Lysate of mock-infected A549 cells was run in parallel to control for specificity
of the HA band. (E) A549 control cells (con) or CtsW-overexpressing cells were infected with A/WSN/33 (MOI of 50) for 60 min on ice and then transferred to
37°C for 60 or 120 min before they were lysed. Viral protein levels were analyzed by Western blotting using antibodies against HA, NA, NP, M1, CtsW, and
GapDH as loading control. The asterisk marks the NP band visible above the NA band, as the blot was first stained for NP and subsequently for NA. In panels A
to E, the results from one experiment representative of at least two independent experiments are shown.
Edinger et al.
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DISCUSSION
Genome-wide RNAi screens have discovered a plethora of cellular
factors that influenza viruses hijack for their replication (14–18). The
lists of identified factors hold great potential to reveal new aspects of
the virus-host interplay and thereby uncover novel details about cel-
lular processes. Moreover, such required cellular proteins represent
potential drug targets, as shown by König et al. (15) and Stertz and
Shaw (34). However, to date, there has been little follow-up on the
identified factors, and so far, no promising drug target has emerged
from the screens. In this study,we characterizedCtsW,oneof thehits
identified in a genome-wide RNAi screen, and show that CtsW is
required for fusion of influenza viruswith the endosomalmembrane
and subsequent escape of IAV into the cytoplasm. The proviral func-
tion of CtsW required its catalytic activity, and therefore, we suggest
that CtsW could be a potential drug target worth exploring for the
development of novel antiviral agents.
Our data show that knockdown of CtsW by siRNAs leads to
reduced virus titers for a number of different strains of IAV
(Fig. 1). This was not due to off-target effects of the siRNAs, since
six different siRNAs against CtsW resulted in the same phenotype
(Fig. 2) and reintroduction of CtsW expression rescued the inhi-
bition of IAV (Fig. 6). These data suggest a specific role for CtsW
that cannot be compensated for by other cathepsins. In line with
this hypothesis, we did not detect inhibition of IAV by inhibitors
of cathepsin L and cathepsin B (data not shown).
We then mapped the step of the viral replication cycle that
required CtsW and found that by 3 h p.i., the amount of nuclear
NP was already strongly decreased upon CtsW knockdown
(Fig. 2). Finer mapping of the target step revealed that virus at-
tachment, internalization, and early endosomal trafficking were
not affected. However, escape of IAV from the late endosome was
blocked, and viral fusion was strongly inhibited upon CtsW
knockdown (Fig. 3 and 4). We therefore conclude that CtsW is
required for fusion or a step just before the fusion event.While we
have a detailed understanding of the functions of the viral proteins
in the fusion event (9), little is known about the cellular players
involved. Early on, it was observed that low pH is required for
fusion and that the endosomal VATPase complex is needed to
FIG 6 The catalytic activity of cathepsin W is required for IAV entry. (A)
A549 cells were transduced using a lentiviral system to generate stable cell lines
expressing wild-type CtsW (CtsW_res #2) or mutant CtsW(C153A)
(C153A_res #2), bothmade resistant to siCtsW #2 by the introduction of three
silent mutations into the target site of siCtsW #2. A549 cells transduced with a
lentivirus carrying no insert were used as controls (con). Cells were transfected
with siRNAs as indicated, and CtsW expression was assessed byWestern blot-
ting using a mouse monoclonal antibody against CtsW and an antibody
against GapDH as loading control. (B and C) A549 control cells or cells stably
expressing CtsW (wild type ormutant) were transfectedwith siRNAs targeting
CtsW or a nontargeting control. At 48 h posttransfection, cells were infected
with A/WSN/33 with an MOI of 10 for 3 h. Cells were stained using a mouse
monoclonal anti-NP antibody (plus secondary antibody anti-mouse AF488)
and DAPI. Representative images are shown in panel B. Bars, 10 m. (C)
Nuclear NP was quantified using ImageJ software. For significance testing, a
two-tailed Student’s t test was performed (n  150). Values that are signifi-
cantly different are indicated by bars and asterisks as follows: ****, P 0.0001.
Values that are not significantly different (P  0.05) are indicated (n.s.). (D)
Experimental setup as described above for panel B, but stainingwas performed
using a rabbit polyclonal serum against NP and amousemonoclonal antibody
against CtsW. For quantification of nuclear NP, only cells expressing CtsW
were included in the analysis. For significance testing, a two-tailed Student’s
t test was performed (n 90). In panels A to D, the results of one experiment
representative of three independent experiments are shown.
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provide the low-pH environment in the endosome (8, 35, 36).
Recently, the tetraspanin CD81 was identified as a second cellular
player in the fusion process, but so far, we do not understand how
CD81 exerts its function (37). With this study, we have identified
a novel player in the fusion process, CtsW.
When analyzing the subcellular localization of CtsW,we found
that a significant fraction of theCtsW staining colocalizedwith the
ER-resident chaperone calnexin (Fig. 4). This is consistent with
previous findings, which reported ER localization of CtsW (26, 28,
29). Interestingly, we also detected colocalization with a late en-
dosomal marker (Fig. 4), and we therefore assume that at least a
fraction of CtsW localizes to late endosomes. This would be con-
sistent with a function of CtsW before or during the viral fusion
process which takes place in the late endosome.
Notably, we detected two easily separable bands for CtsW on
Western blots; the top band could sometimes be observed as a
doublet. In contrast, only a single band could be detected for the
catalytically inactive mutant. Thus far, we can only speculate that
the additional bands representmodified forms, as this will require
further studies. From results obtained with the catalytically inac-
tive mutant (Fig. 6), we hypothesize that CtsW cleaves a yet un-
known target in the late endosome and that this proteolytic cleav-
age event is important for fusion of the viral and endosomal
membranes. This proteolytic cleavage event does not seem to im-
pact endosomal pH. First, knockdown of CtsW did not result in
detectable changes of the lysotracker signal, which marks acidic or-
ganelles (Fig. 5) (38). Second, a strain of IAV that had been shown to
have ahigherpHoptimumfor fusion (pH5.5 to 5.6 versuspH5.2 for
A/WSN/33) was inhibited by knockdown of CtsW to an extent sim-
ilar to that of strain A/WSN/33 (Fig. 5) (30). Instead, we hypothesize
that the low pH is rather a requirement for CtsW function, as shown
for other cathepsin family members (39, 40). The substrate that is
cleaved by CtsW and then enables fusion to occur has yet to be iden-
tified. As we used trypsin-treated virus stocks for all experiments, we
did not expect to find a role for CtsW in HA cleavage from HA0 to
HA1 andHA2.Moreover, strainA/FPV/Dobson/34which contains a
multibasic cleavage site in its HA protein was also sensitive to CtsW
knockdown (Fig. 1). Therefore, we speculated that additional cleav-
age events could occur in HA or NA, but our experiments aiming to
detect such cleavage events during the early stages of viral entry did
not show any differences between control cells and cells overexpress-
ing CtsW (Fig. 5). This could be indicative of cellular proteins being
cleavedordegradedbyCtsW, rather thanviral proteins.However,we
cannot exclude the possibility that a small fraction of a viral protein is
targeted by CtsW but not detected by ourWestern blot setting.
In summary, this study establishes CtsW as a novel cellular
factor required for entry of IAV into target cells at the stage of
fusion between viral and endosomal membranes. The proteolytic
activity of CtsW is needed for its proviral function and thereby
presents a potential drug target for future development of new
antivirals against influenza.
MATERIALS AND METHODS
Cells and viruses. A549 lung epithelial cells (ATCC CCL185), Wi38 lung
fibroblast cells (ATCC CCL75), Vero, 293T (ATCC CRL 3216), andMDCK
cells (ATCC CCL34) were grown in Dulbecco modified Eagle medium
(DMEM) (Life Technologies) supplemented with 10% fetal calf serum and
1% penicillin-streptomycin (DMEM growth medium). Influenza A virus
strains A/WSN/33 (H1N1), A/Hongkong/68 (H3N2), and A/duck/Ukraine/
1/1963 (kindlyprovidedbyL.Hangartner,University ofZurich, Switzerland)
were grown in 10-day-old embryonated chicken eggs; strain A/FPV/Dob-
son/34 (H7N7)was grown inVero cells. Vesicular stomatitis virus (VSV)was
grown inVerocells.The titersof virus stocksweredeterminedbyplaqueassay
onMDCK or Vero cells. LCMVwas kindly provided by S. Kunz, University
Hospital of Lausanne, Lausanne, Switzerland)
Plasmids and antibodies. The expression construct pCAGGS-CtsW
was generated byPCRamplifying the cDNAofCtsW fromplasmid pCMV6-
XL4-CTSW (CMV stands for cytomegalovirus) (catalog no. SC125558; Ori-
gene) using the forward primer 5=-GACAGAATTCACCATGGCACTGACT
GCCCACC-3= and reverse primer 5=-GACACTCGAGTCAGGGAGGGCA
GGAGACTCGGGGC-3= and cloning it into pCAGGS using EcoRI and
XhoI.TheplasmidpCAGGS-Flag-CtsWwasconstructed in the samewaybut
using a different forward primer, 5=-GACAGAATTCATGGACTATAAGGA
CGACGACGACAAGGGGGTGGCACTGACTGCCCACC-3=. Next, three
silentmutationswere introduced into the cDNAofCtsW tomake it resistant
toknockingdownbysiCtsW#2usingaQuikChangemutagenesiskit (Agilent
Technologies) and the following primers: forward, 5=-GGCCCCATCACCG
TGACAATAAATATGAAGCCCCTTCAGC-3=, and reverse, 5=-GCTGAAG
GGGCTTCATATTTATTGTCACGGTGATGGGGCC-3=. The catalytically
inactive mutant CtsW(C153A) was also generated by using a QuikChange
mutagenesis kit with the following primers: forward, 5=-CCAGAAAAACTG
CAACTGCGCCTGGGCCATGGCAGCGGCAGGCA-3=, and reverse, 5=-
TGCCTGCCGCTGCCATGGCCCAGGCGCAGTTGCAGTTTTTCTG-
3=. The cDNAs of CtsWsiRes and CTSW(C153A)siRes were amplified by PCR
using the forward primer 5=-GACAGAATTCACCATGGCACTGACTGCC
CACC-3= and reverse primer 5=-GACATCTAGATCAGGGAGGGCAGGA
GACTCGGGGC-3=, and the cDNAs were cloned into the lentiviral vector
pLVX-IRES-puro (IRES stands for internal ribosomal entry site, and puro
stands for puromycin) (catalog no. 632183; Clontech) with EcoRI and
XbaI. The resulting constructs pLVX-CtsWsiRes-IRES-puro and pLVX-
CtsW(C153A)siRes-IRES-puro were verified by sequencing.
For Western blotting and immunofluorescence, the following pri-
mary antibodies were used: mouse monoclonal CTSW antibody (catalog
no. WH0001521M1; Sigma-Aldrich), horseradish peroxidase (HRP)-
conjugated glyceraldehyde-3-phosphate dehydrogenase (GAPDH) anti-
body (HRP conjugate [sc-25778; Santa Cruz]), mouse monoclonal M1
antibody (ATCCHB64), rabbit polyclonal NP antibody forWestern blot-
ting (kind gift of A. Nieto, Centro Nacional de Biotecnología, Madrid,
Spain), rabbit polyclonal NP antibody for immunofluorescence (kind gift
of P. Palese, Mount Sinai Hospital, NY, USA), mouse monoclonal HA
antibody (41), rabbit polyclonal NA antibody (catalog no. PA5-32238;
Thermo Scientific), mouse monoclonal EEA1 antibody (catalog no.
610457; BDBioscience), mousemonoclonal LBPA [also called bis(mono-
acylglyceryl)phosphate (BMP)] antibody (catalog no. Z-PLBPA; Echelon
Bioscience), mouse monoclonal LCMVNP antibody (kindly provided by
S. Kunz, University Hospital of Lausanne, Lausanne, Switzerland), rabbit
polyclonal calnexin antibody (catalog no. 22595; Abcam), rabbit poly-
clonal LAMP1 antibody (ab24170; Abcam), and a rabbit polyclonal Flag
antibody (ab1162; Abcam).
Western blot analysis. For Western blot analysis, cells were lysed us-
ing Laemmli buffer (62.5 mM Tris-HCl [pH 6.8], 25% glycerol, 2% SDS,
350 mM dithiothreitol [DTT], 0.01% bromophenol blue), and lysates
were run on 10 to 12% SDSpolyacrylamide gels. Proteins were trans-
ferred to a Hybond ECL nitrocellulose membrane (Fisher Scientific). Fol-
lowing transfer, the membrane was blocked by using 3% milk powder in
Tris-buffered saline (TBS) supplemented with 0.05% Tween 20 (TBS-T).
Primary and secondary antibodies were diluted in TBS-T with 3% milk
powder and incubated with the membrane at room temperature (RT) for
1 to 2 h. Enhanced chemiluminescent (ECL) substrate (Thermo Scien-
tific) was used for detection of protein bands.
DNAand siRNA transfection.All siRNAswere purchased fromQiagen
and transfected using Lipofectamine RNAimax (catalog no. 13778-150; Life
Technologies). A549 cells were reverse transfected with siRNA according to
the manufacturer’s protocol. The final concentration of all siRNAs was
30 nM. After 48 h, the transfection efficiency was controlled by cell death of
Edinger et al.
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siRPS27A-treated cells. Cell viability was monitored using CellTiter-Glo lu-
minescent cell viability assay (catalog no. G7570; Promega).
Plasmid transfection was performed using JetPrime (catalog no. 114-
15; Polyplus) according to the manufacturer’s protocol. Plasmid/siRNA
cotransfection was performed using Lipofectamine 2000 (Life Technolo-
gies) as instructed by the manufacturer.
siRNA sequences.All siRNAs (Qiagen)were orderedwith dTdT over-
hang and stored at 20°C. The sequences of the siRNAs are as follows
(Qiagen catalog numbers shown in parentheses): scrambled1777 (custom
siRNA), 5=-AAGCGTTCGTCCTATGATCGA-3=; siCtsW #2 (SI00025494), 5=-
CACCGTGACCATCAACATGAA-3=; siCtsW#3 (SI00025501), 5=-CGCGTTC
ATAACTGTCCTCAA-3=; siCtsW#4 (SI00025508), 5=-CCCAGCATGGGCAG
AGAAATA-3=; siCtsW #5 (SI03079076), 5=-CCCGTGTGCAGAAACCGGAT
A-3=; siCtsW #8 (SI05050577), 5=-CAGCCTGAATAAACCAAGACA-3=;
siCtsW #9 (SI05050584), 5=-CAGCTCTGTCCTGTTAGGCCA-3=; siNP
(custom siRNA), 5=-GGAUCUUAUUUCUUCGGAGTT-3=; siATP6V0C
(SI04195590), 5=-CACAAAGTAGACCCTCTCCGA-3=; and siRPS27A
(SI1027423), 5=-AAGCTGGAAGATGGACGTACT-3=.
Virus infection and titration. For virus infection of A549 or Wi38
cells, phosphate-buffered saline (PBS) was supplemented with 0.02 mM
Mg2, 0.01 mM Ca2, 0.3% bovine serum albumin (BSA), and 1%
penicillin-streptomycin and used to dilute virus stocks. The cells were
washed once prior to infection, and the inoculum was either added at
room temperature or on ice for 60 min to synchronize infection. The
inoculumwas removed and replaced by an appropriate amount of postin-
fection medium (DMEM supplemented with 0.3% BSA, 20 mM HEPES,
and 1% penicillin-streptomycin). Cells were incubated for the indicated
times at 37°C. Infectious titers of samples were determined by plaque
assay onMDCK cells or by infecting A549 cells with serial dilutions of the
samples and subsequent immunofluorescence staining of viral NP to
quantify infectious virus.
Immunofluorescence staining andmicroscopy. For immunofluores-
cence staining, A549 cells were grown on glass coverslips in 24-well plates.
Cells were fixed with 3% paraformaldehyde (PFA) and permeabilized using
immunofluorescence (IF) buffer (PBS supplemented with 50 mM NH4Cl,
0.1%saponin, and2%BSA).After1h in IFbuffer, the cellswere incubated for
1 to 2h atRTorovernight at 4°Cwithprimary antibodies. After the cellswere
incubated with primary antibodies, they were washed three times with IF
buffer before secondary antibodieswere added for 1 to2hatRT.AlexaFluor-
conjugated donkey anti-mouse/rabbit antibodies (catalog no. A-21202,
A-21206, A10036, and A10040; Life Technologies) were used as secondary
antibodies. The cells were washed three times with IF buffer, before the cov-
erslips were dipped in deionized water and inversely mounted onto glass
microscope slides using DAPI (4=,6=-diamidino-2-phenylindole) Fluoro-
mount G (catalog no. 0100-20; Southern Biotech).
All microscopy images were acquired with a confocal laser scanning
microscope (Leica SP5). For colocalization analysis, the Imaris software
with standard colocalization settings was used. Image processing and
quantification of nuclear NP signal, as well as fusion site analysis, were
performed using ImageJ software. Statistical analysis was done using
PRISM software.
Attachment and internalization assay. The attachment and internal-
ization assay was performed as previously described (42). Briefly,
A/WSN/33 was concentrated over a sucrose cushion (30%) and biotinyl-
ated using the EZ-link NHS-SS biotin kit (Thermo Scientific). siRNA-
transfected A549 cells were detached and cooled on ice in fluorescence-
activated cell sorting (FACS) buffer (PBS supplemented with 2% BSA).
Cells were infected on ice with biotinylated A/WSN/33 for 1 h andwashed
thoroughly with FACS buffer. Before the cells were incubated at 37°C for
30 min, they were incubated on ice either with FACS buffer containing
unconjugated streptavidin (2 mg/ml; Life Technologies) or FACS buffer
alone. Following internalization, the cells were either directly fixed with
PFA (3%) or incubated with FACS buffer supplementedwith streptavidin
and sodium azide (0.1%) for 30 min and then fixed. For staining, Cy3-
labeled streptavidin (Life Technologies) diluted in FACS buffer was used.
FACS analysis was performed on a CyAn ADP analyzer (Beckmann
Coulter Inc.), and data were analyzed using FlowJo software.
Fusion assay. Measurement of viral fusion was performed accord-
ing to a protocol previously described (43, 44). Briefly, IAVA/PR/8/34was
labeled using two fluorescent dyes, R18 (octadecyl rhodamine B chloride)
and SP-DiOC18 [3,3=-dioctadecyl-5,5=-di(4-sulfophenyl)oxacarbo-
cyanine] (Life Technologies), at a ratio of 1:2 with final concentrations of
R18 of 22 M and SP-DiOC18 of 46 M. After intense vortexing for 60
min at RT, labeled virus was filtered through a 0.22-m-pore-size filter.
Virus was bound to cells for 30 min at a cold temperature (4°C), and after
the cells were washed with PBS, the temperature was shifted to 37°C for 0,
90, or 180 min. Unfixed and unpermeabilized samples were mounted.
Image analysis was carried out using the spot analysis function of ImageJ
for SP-DiOC18 staining with a distinct spot size of 20 pixels and a subse-
quent correction for cell numbers.
Lysotracker. Lysotracker red DND-99 (catalog no. L7528; Life Tech-
nologies) was diluted in DMEM growth medium and added to cells at a
final concentration of 25 nM. The cells were then incubated at 37°C for 30
min, washed once with medium, and mounted without fixation or per-
meabilization.
Lentivirus production and transduction of A549 cells. To produce
lentiviral particles, 293T cells were transfectedwith pLVX-CtsWsiRes-IRES
puro (wild type or mutant), a plasmid encoding VSVG protein (VSV-G),
and an expression plasmid forHIV gag-pol using FuGeneHD transfection
reagent (Promega). Supernatants containing the lentiviral particles were
harvested 48 h after transfection and supplemented with Polybrene (final
concentration, 8 g/ml). For transduction, A549 cells were seeded at low
density, infectedwith the lentiviral particles, and kept at 37°C for 48 h. The
medium was then changed to DMEM growth medium with 10 ng/ml
puromycin. Selection was maintained during subsequent culture.
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